Skip to main
LLY
LLY logo

Eli Lilly (LLY) Stock Forecast & Price Target

Eli Lilly (LLY) Analyst Ratings

Based on 15 analyst ratings
Buy
Strong Buy 47%
Buy 40%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Eli Lilly's strong performance in the second quarter of 2025, characterized by both top and bottom-line growth and an increase in fiscal year guidance, signifies robust financial health. Notably, the company's Mounjaro product experienced impressive international sales growth of 60% quarter-over-quarter, bolstered by successful market entries in Brazil, Mexico, and India. Additionally, the anticipated launch of orforglipron is expected to further enhance Lilly's position in the GLP-1 market with its innovative oral formulation, potentially driving additional revenue streams.

Bears say

The analysis of Eli Lilly's stock indicates a number of critical concerns that support a negative outlook. There are significant risks associated with potential pricing and rebate pressures, coupled with a disappointing trajectory for tirzepatide prescriptions, and its inability to demonstrate cardiac outcome benefits in key patient populations. Additionally, the negative impact on Zepbound prescriptions and the competitive threat posed by orforglipron, which outperforms expectations for similar products, further exacerbate these challenges, leading to lowered sales forecasts and overall market uncertainty.

Eli Lilly (LLY) has been analyzed by 15 analysts, with a consensus rating of Buy. 47% of analysts recommend a Strong Buy, 40% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Eli Lilly and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Eli Lilly (LLY) Forecast

Analysts have given Eli Lilly (LLY) a Buy based on their latest research and market trends.

According to 15 analysts, Eli Lilly (LLY) has a Buy consensus rating as of Oct 23, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $957.27, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $957.27, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Eli Lilly (LLY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.